Communications Medicine (Sep 2024)

Graft survival of major histocompatibility complex deficient stem cell-derived retinal cells

  • Masaaki Ishida,
  • Tomohiro Masuda,
  • Noriko Sakai,
  • Yoko Nakai-Futatsugi,
  • Hiroyuki Kamao,
  • Takashi Shiina,
  • Masayo Takahashi,
  • Sunao Sugita

DOI
https://doi.org/10.1038/s43856-024-00617-5
Journal volume & issue
Vol. 4, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Background Gene editing of immunomodulating molecules is a potential transplantation strategy to control immune rejection. As we noticed the successful transplantation of retinal pigment epithelium (RPE) derived from embryonic stem cells of a cynomolgus monkey that accidentally lacked MHC class II (MHC-II) molecules, we hypothesized immune rejection could be evaded by suppressing MHC-II. Methods Gene editing by the Crispr/Cas9 system was performed in induced pluripotent stem cells derived from a cynomolgus monkey (miPSCs) for targeted deletion of the gene coding class II MHC trans-activator (CIITA). Then the CIITA-knocked out miPSCs were differentiated into RPE cells to generate miPSC-derived MHC-II knockout RPE. The MHC-II knockout or wild-type RPEs were transplanted into the eyes of healthy cynomolgus monkeys. All monkeys used in this study were male. Results Here we show when MHC-II knockout RPE are transplanted into monkey eyes, they show suppressed immunogenicity with no infiltration of inflammatory cells, leading to successful engraftment. Conclusions Our results reasonably evidence the efficacy of MHC-II knockout iPSC-RPE transplants for clinical application.